AbbVie Inc ABBV
News
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
AbbVie Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since September 2016 — Data Talk
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
AbbVie Completes Acquisition of Landos Biopharma
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
AbbVie to Present at the Bank of America Securities Healthcare Conference
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises
AbbVie's first-quarter results top expectations as arthritis drugs fuel growth
AbbVie Reports First-Quarter 2024 Financial Results